HBV/HCV/HIV serology + dental evaluation pre-bisphosphonate/denosumab + DPYD genotyping f...

Детермінований перегляд YAML-сутності з джерельної бази. Клінічний авторитет лишається за вказаними source ID та статусом клінічного sign-off.

ID	`RF-BREAST-INFECTION-SCREENING`
Тип	Тривожна ознака
Статус	очікує клінічного підпису
Хвороби	`DIS-BREAST`
Джерела	`SRC-ESMO-BREAST-EARLY-2024` `SRC-NCCN-BREAST-2025`

Походження тривожної ознаки

Визначення	HBV/HCV/HIV serology + dental evaluation pre-bisphosphonate/denosumab + DPYD genotyping for capecitabine-containing regimens (EU practice).
Клінічний напрям	investigate
Категорія	infection-screening

Логіка спрацьовування

{
  "any_of": [
    {
      "finding": "hbsag",
      "value": "positive"
    },
    {
      "finding": "dental_clearance_pending",
      "value": true
    },
    {
      "finding": "dpyd_deficient",
      "value": true
    }
  ],
  "type": "composite_clinical"
}

Нотатки

Cross-disease HBV reactivation handled by RF-UNIVERSAL-HBV-REACTIVATION- RISK. DPYD deficiency screening unique to fluoropyrimidine-containing regimens; severe / fatal toxicity in homozygous deficient patients — EU/EMA-recommended pre-test.

Де використовується

Indications

IND-BREAST-BRCA-MET-TALAZOPARIB - IND-BREAST-BRCA-MET-TALAZOPARIB
IND-BREAST-BRCA-POS-MET-PARPI - IND-BREAST-BRCA-POS-MET-PARPI
IND-BREAST-HER2-LOW-2L-DATO-DXD - IND-BREAST-HER2-LOW-2L-DATO-DXD
IND-BREAST-HER2-POS-3L-TUCATINIB - IND-BREAST-HER2-POS-3L-TUCATINIB
IND-BREAST-HER2-POS-EARLY-NEOADJUVANT - IND-BREAST-HER2-POS-EARLY-NEOADJUVANT
IND-BREAST-HER2-POS-MAINT-TRAST - IND-BREAST-HER2-POS-MAINT-TRAST
IND-BREAST-HER2-POS-MET-1L-THP - IND-BREAST-HER2-POS-MET-1L-THP
IND-BREAST-HER2-POS-MET-2L-TDXD - IND-BREAST-HER2-POS-MET-2L-TDXD
IND-BREAST-HR-POS-1L-INAVOLISIB - IND-BREAST-HR-POS-1L-INAVOLISIB
IND-BREAST-HR-POS-2L-AKT-CAPIVASERTIB - IND-BREAST-HR-POS-2L-AKT-CAPIVASERTIB
IND-BREAST-HR-POS-2L-DATO-DXD - IND-BREAST-HR-POS-2L-DATO-DXD
IND-BREAST-HR-POS-2L-ESR1-ELACESTRANT - IND-BREAST-HR-POS-2L-ESR1-ELACESTRANT
IND-BREAST-HR-POS-2L-FUL-EVEROLIMUS - IND-BREAST-HR-POS-2L-FUL-EVEROLIMUS
IND-BREAST-HR-POS-2L-PIK3CA-ALPELISIB - IND-BREAST-HR-POS-2L-PIK3CA-ALPELISIB
IND-BREAST-HR-POS-2L-T-DXD-HER2-LOW - IND-BREAST-HR-POS-2L-T-DXD-HER2-LOW
IND-BREAST-HR-POS-3L-POST-CDK46I-POST-AKT - IND-BREAST-HR-POS-3L-POST-CDK46I-POST-AKT
IND-BREAST-HR-POS-MAINT-CDK46I - IND-BREAST-HR-POS-MAINT-CDK46I
IND-BREAST-HR-POS-MET-1L-CDKI - IND-BREAST-HR-POS-MET-1L-CDKI
IND-BREAST-TNBC-2L-BRCA-OLAPARIB - IND-BREAST-TNBC-2L-BRCA-OLAPARIB
IND-BREAST-TNBC-2L-BRCA-TALAZOPARIB - IND-BREAST-TNBC-2L-BRCA-TALAZOPARIB
IND-BREAST-TNBC-2L-DATO-DXD - IND-BREAST-TNBC-2L-DATO-DXD
IND-BREAST-TNBC-2L-SACITUZUMAB - IND-BREAST-TNBC-2L-SACITUZUMAB
IND-BREAST-TNBC-2L-T-DXD-HER2-LOW - IND-BREAST-TNBC-2L-T-DXD-HER2-LOW
IND-BREAST-TNBC-3L-POST-SACI-POST-T-DXD - IND-BREAST-TNBC-3L-POST-SACI-POST-T-DXD
IND-BREAST-TNBC-EARLY-NEOADJUVANT - IND-BREAST-TNBC-EARLY-NEOADJUVANT
IND-BREAST-TNBC-METASTATIC-1L-PEMBRO-CHEMO - IND-BREAST-TNBC-METASTATIC-1L-PEMBRO-CHEMO